Shots:

• In Aug- 2018 naxitamab received the US FDA’s Breakthrough Therapy Designation for the treatment of high-risk neuroblastoma
• The rolling review process of the US FDA provides to submit individual portions of the BLA for review- rather than waiting until all portions are completed and submitted to the FDA for review
• Naxitamab is an anti-GD2 mAb and has received Orphan Drug Status from the US FDA in both neuroblastoma and osteosarcoma- and is currently in a P-II clinical trial for MSK

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Behance